The effect of infliximab on hepatic cytochrome p450 and pharmacokinetics of verapamil in rats with pre-adjuvant arthritis: A drug-disease and drug-drug interaction

Basic and Clinical Pharmacology and Toxicology

Volumn 105, Issue 1, 2009, Pages 24-29

  Ling, Spencer ^a   Jamali, Fakhreddin ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 3A; ENZYME; INFLIXIMAB; NITRITE; VERAPAMIL;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; DRUG METABOLISM; DRUG PROTEIN BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMOBILIZATION; INJECTION; LIMB SWELLING; MALE; MYCOBACTERIUM BUTYRICUM; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RACEMIZATION; RAT; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; SYMPTOM; TAIL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; C-REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; LIVER; MALE; NITRITES; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; VERAPAMIL;

ANIMALIA; MYCOBACTERIUM BUTYRICUM; RATTUS;

EID: 67651205738     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00405.x     Document Type: Article

References (26)

1. Mayo PR, Skeith K, Russell AS, Jamali F. Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br J Clin Pharmacol 2000 50 : 605 13.
2. Ling S, Jamali F. Effect of early phase adjuvant arthritis on hepatic P450 enzymes and pharmacokinetics of verapamil: an alternative approach to the use of an animal model of inflammation for pharmacokinetic studies. Drug Metab Dispos 2005 33 : 579 86.
3. Walker KA, Barber HE, Hawksworth GM. Mechanism responsible for altered propranolol disposition in adjuvant-induced arthritis in the rat. Drug Metab Dispos 1986 14 : 482 6.
4. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007 21 : 885 906. (Pubitemid 47377810)
5. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999 100 : 2124 6.
6. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003 108 : 2957 63.
7. Guirguis MS, Jamali F. Disease-drug interaction: Reduced response to propranolol despite increased concentration in the rat with inflammation. J Pharm Sci 2003 92 : 1077 84.
8. Kulmatycki KM, Abouchehade K, Sattari S, Jamali F. Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat. Br J Pharmacol 2001 133 : 286 94.
9. Sattari S, Dryden WF, Eliot LA, Jamali F. Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. Br J Pharmacol 2003 139 : 945 54.
10. Kulmatycki KM, Jamali F. Drug disease interactions: role of inflammatory mediators in disease and variability in drug response. J Pharm Pharm Sci 2005 8 : 602 25.
11. Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1993 348 : 332 7.
12. Lowry OH, Rosebough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951 193 : 265 75.
13. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964 239 : 2370 8.
14. Shibukawa A, Wainer IW. Simultaneous direct determination of the enantiomers of verapamil and norverapamil in plasma using a derivatized amylose high-performance liquid chromatographic chiral stationary phase. J Chromatogr 1992 574 : 85 92.
15. Grisham MB, Johnson GG, Lancaster JR, Jr. Quantitation of nitrate and nitrite in extracellular fluids. Methods Enzymol 1996 268 : 237 46.
16. Pietila KO, Harmoinen AP, Jokiniitty J, Pasternack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 1996 17 : 1345 9.
17. Verheggen PW, de Maat MP, Cats VM, Haverkate F, Zwinderman AH, Kluft C et al. Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. Eur Heart J 1999 20 : 567 74.
18. Khatsenko OG, Gross SS, Rifkind AB, Vane JR. Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants. Proc Natl Acad Sci U SA 1993 90 : 11147 51.
19. Perkins DJ, St Clair EW, Misukonis MA, Weinberg JB. Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor α monoclonal antibody (cA2). Arthritis Rheum 1998 41 : 2205 10.
20. Vuolteenaho K, Moilanen T, Hamalainen M, Moilanen E. Effects of TNFα-antagonists on nitric oxide production in human cartilage. Osteoarthritis Cartilage 2002 10 : 327 32.
21. Saud B, Nandi J, Ong G, Finocchiaro S, Levine RA. Inhibition of TNF-α improves indomethacin-induced enteropathy in rats by modulating iNOS expression. Dig Dis Sci 2005 50 : 1677 83.
22. Bush KA, Kirkham BW, Walker JS. The in vivo effects of tumour necrosis factor blockade on the early cell mediated immune events and syndrome expression in rat adjuvant arthritis. Clin Exp Immunol 2002 127 : 423 9.
23. Gibaldi M, Perrier D. Pharmacokinetics. Marcel Dekker, New York. 1982.
24. Sirmagül B, Ozdener F, Gulbas Z, Erol K. Calcium channel blockers increase the amount of nitrite production in rabbits without decreasing the responsiveness of platelets to collagen. Clin Exp Med 2007 7 : 142 8.
25. Clements JD, Jamali F. Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. Vascul Pharmacol 2007 46 : 52 9.
26. Hanafy S, Dagenais NJ, Dryden WF, Jamali F. Effects of angiotensin II blockade on inflammation-induced alterations of pharmacokinetics and pharmacodynamics of calcium channel blockers. Br J Pharmacol 2008 153 : 90 9.